Formoterol 12 mcg

DRUG2 trials

Sponsors

Boehringer Ingelheim, Novartis Pharmaceuticals

Conditions

AsthmaPersistent Asthma

Phase 2

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

CompletedNCT01013753

Boehringer IngelheimAsthma

Start: 2010-02-28End: 2011-01-31Updated: 2014-06-27

Phase 4

Study of Safety of Foradil in Patients With Persistent Asthma

TerminatedNCT01845025

Novartis PharmaceuticalsPersistent Asthma

Start: 2013-05-31End: 2016-05-31Updated: 2017-03-21

Related Papers

Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study

Respiratory Research2015-08-1713 citations

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.

2015-07-167 citations